Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd. Show more

Location: 645 Summer Street, Boston, MA, 02210, United States | Website: https://ikenaoncology.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

718.8M

52 Wk Range

$1.36 - $23.28

Previous Close

$14.74

Open

$14.54

Volume

6,821

Day Range

$14.00 - $14.73

Enterprise Value

-20.96M

Cash

95.64M

Avg Qtr Burn

-7.296M

Insider Ownership

8.00%

Institutional Own.

76.21%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.